Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid
| Autor: | Jan Ernerudh, Charlotte Dahle, Måns Edström, Johan Mellergård, Magnus Vrethem |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male Medicin och hälsovetenskap Chemokine Time Factors medicine.medical_treatment Down-Regulation chemokines Antibodies Monoclonal Humanized multiple sclerosis Medical and Health Sciences cerebrospinal fluid Young Adult Multiple Sclerosis Relapsing-Remitting natalizumab Natalizumab medicine Humans Immunologic Factors CCL17 CXCL10 CXCL11 biology business.industry Multiple sclerosis Antibodies Monoclonal Middle Aged peripheral blood medicine.disease cytokines Treatment Outcome Cytokine Neurology Immunology biology.protein Cytokines luminex CXCL9 Female Neurology (clinical) Chemokines business Biomarkers medicine.drug |
| Zdroj: | Multiple Sclerosis Journal. 16:208-217 |
| ISSN: | 1477-0970 1352-4585 |
| Popis: | Natalizumab exerts impressive therapeutic effects in patients with multiple sclerosis (MS). The proposed main mode of action is reducing transmigration of leukocytes into the CNS, but other immunological effects may also be operative. Cytokines and chemokines are involved in the regulation of inflammatory responses and may reflect the disease process in MS. The objective of this study was to evaluate the effects of natalizumab treatment on cytokine and chemokine profiles systemically and intrathecally in multiple sclerosis. We used luminex to analyse a panel of cytokines (IL-1 beta, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, TNF-alpha, IFN-gamma, GM-CSF) and chemokines (CXCL9, CXCL10, CXCL11, CCL17, CCL22) in blood and cerebrospinal fluid (CSF) from 31 patients with relapsing MS before and after one year of natalizumab treatment. There was a marked decline in CSF levels of cytokines and chemokines, thus including pro-inflammatory cytokines (IL-1 beta, IL-6 and IL-8) as well as chemokines associated with both Th1 (CXCL9, CXCL10, CXCL11) and Th2 (CCL22). Circulating plasma levels of some cytokines (GM-CSF, TNF-alpha, IL-6 and IL-10) also decreased after one year of treatment. This is the first study to show that natalizumab treatment is associated with a global decline in cytokine and chemokine levels at a protein level. This finding was most pronounced in CSF, in line with the reduced transmigration of cells into CNS, whereas reduction in plasma levels indicates other possible mechanisms of natalizumab treatment. Original Publication: Johan Mellergård, Måns Edström, Magnus Vrethem, Jan Ernerudh and Charlotte Dahle, Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid, 2010, MULTIPLE SCLEROSIS, (16), 2, 208-217. http://dx.doi.org/10.1177/1352458509355068 Copyright: SAGE Publications http://www.uk.sagepub.com/ |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|